arx517
Generic: Anti-PSMA Antibody-drug Conjugate ARX517·Code: ARX517
arx517: developed by 1 company · 1 clinical trial tracked.
arx517 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect arx517 to AMAM; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could arx517 → AMAM affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 1 study sponsors
Related indications
Prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC)Metastatic Prostate Cancer
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| Ambrx Biopharma Cayman, Inc. (AMAM) Prostate cancer, including metastatic castration-resistant p… | Phase 1 |
Clinical Trials (1)
A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer
Primary endpoint: Assess incidence of adverse events
Interventionalopen183 targetStarted 2021-05Completion 2026-1212 sites · United StatesJanssen Research & Development, LLC
Frequently asked questions
Who is developing arx517?
arx517 is being developed by Ambrx Biopharma Cayman, Inc..
How many clinical trials involve arx517?
BioSniper tracks 1 clinical trial involving arx517.